Abstract:Hypoxia is a common phenomenon in human solid tumors and has been considered as an important, independent negative prognostic factor for response to treatment and survival of tumor patients. Hypoxia-inducible factor-1 (HIF-1) is the central transcription factor which is activated by hypoxia and modulates the expression of many genes involved in cell metabolism, proliferation, apoptosis, angiogenesis. Recently, it has been reported that HIF-1 contributes to tumor radioresistance by upregulating survivin expression under hypoxic conditions. Moreover, in hypoxic tumor cells, HIF-1 dependent signal transduction pathway is activated and could be further enhanced by radiation, thereby providing survival signals to adjacent vascular endothelial cells by upregulation of VEGF and bFGF and resulting in tumor radioresistance through vascular radioprotection. Recent research revealed that the stability of HIF-1α, one of the two subunits of HIF-1, determines the whole HIF-1 activity and the C-terminal transactivation domain of HIF-1α could reduce HIF-1 activity when overexpressed in tumor cells by disruption of the assembly of HIF-1 transcription complex. Therefore, we postulate that fusion with protein transduction domains would overcome the inability of C-terminal transactivation domain of HIF-1α to cross cellular membrane. Thus the recombinant fusion proteins could serve as cell-permeable HIF-1 antagonists, function as both inhibitors of tumor angiogenesis and tumor radiosensitizers, and would be widely used in clinical settings to improve tumor response to radiotherapy.

[Hypoxia-Inducible Factor-1Alpha: a Promising Target for Tumor Therapy].

Hypoxia Inducible Factor-1 alpha: A New Anticancer Drug Target

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

Cancer Therapy by Targeting Hypoxia-Inducible Factor-1.

Progress of Hypoxia-inducing Factor 1

Hypoxia inducible factor-1α and oral tumor therapy

Recent Agents Targeting Hif-1 Alpha For Cancer Therapy

Small Molecules Targeting HIF-1α Pathway for Cancer Therapy in Recent Years

Hypoxia-inducible factor-1 in tumour angiogenesis.

Advances in the research and development of HIF-1 inhibitors

Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy

Recent Progress in the Study on Antitumor Drugs Targeting Hypoxia-Inducible Factor-1

The Reseach Development of Hypoxia-inducible Factor-1 and Tumor Cell Apoptosis

Hypoxia-inducible Factor-1 in Tumour Angiogenesis

Hypoxia and Hypoxia-inducible Factor-1α:Master Regulators of Tumor Metastasis

Targeting Hypoxia-Inducible Factor-1, for Cancer Treatment: Recent Advances in Developing Small-Molecule Inhibitors from Natural Compounds.

HIF-1α pathway: role, regulation and intervention for cancer therapy

Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.

Effect of hypoxia-inducible factor -1(HIF-1) and target genes on malignant tumor progression

Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy